CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 139 enrolled
Drug / intervention
prasugrel 10 mg +4 moredrug
Likely dose
prasugrel 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00356135
NCT00356135Phase 2Completed
CompareCT.gov

A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus Clopidogrel in Subjects With Acute Coronary Syndrome Who Are Receiving Clopidogrel

Eli Lilly and Company·interventional·Posted Jul 25, 2006·Updated Nov 3, 2010

In Brief

A Phase 2 clinical trial evaluating prasugrel 10 mg, clopidogrel, and 3 other interventions for Coronary Arteriosclerosis and Acute Coronary Syndrome. Completed, enrolled 139 participants across 9 sites.

Detailed Summary

This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (PCI) with placement of a stent, performed to treat acute coronary syndrome (ACS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Arteriosclerosis, Acute Coronary Syndrome
CountriesUnited States
CollaboratorsDaiichi Sankyo

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 25, 2006
Enrollment StartJul 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.9 years ago

Interventions

prasugrel 10 mgdrug

10 mg tablet taken orally

clopidogreldrug

75 mg tablet taken orally

prasugrel placebodrug

oral, as blinding mechanism.

prasugrel 60 mgdrug

60 mg (six 10-mg tablets) taken orally

clopidogrel placebodrug

oral, as blinding mechanism